Skip to main content Skip to accessibility tools

A prospective observational study to measure platelet inhibition by aspirin administered for reactive thrombocytosis in Pseudomyxoma Peritonei patients

Study ID: 54712
Short Title: Platelet inhibition for reactive thrombocytosis in pseudomyxoma
Trust Name: HHFT
Recruitment Site: Basingstoke and North Hampshire Hospital
Disease Area: Colorectal cancer Urology
Phase: N/A
Expected End Date: 28/02/2025
Postcode: RG24 9NA
SO22 5DG
Contact Name: Amanda Pattie
Contact Email: studysupport1and3.crnwessex@nihr.ac.uk
Active: Yes

Patients > 18 years of age Diagnosis of Pseudomyxoma Peritonei Patients undergoing CRS and HIPEC

Patients < 18 years of age Having CRS and HIPEC for other conditions apart from Pseudomyxoma Peritonei Allergic to aspirin On other antiplatelet or drugs that affect platelet function e.g. NSAIDs Ischaemic vascular events, percutaneous coronary intervention, or coronary artery bypass within the last 12 months

Pseudomyoma peritonei is a rare abdominal cancer that arises from the appendix. The current treatment is major surgery and heated chemotherapy which is administered directly into the abdomen. After surgery some patients develop reactive thrombocytosis (high platelet counts) which may cause abnormal blood clots. For this reason patients are given 75mg of aspirin prophylactically to inhibit platelets for a period of approximately 6 weeks. Although these patients are given aspirin we do not know currently how effective the aspirin is in blocking platelets as some patients do not respond to aspirin, a phenomenon known as 'aspirin resistance' or 'aspirin treatment failure'. This study aims to identity patients who are aspirin resistant using VerifyNow, a point of care test that measures how effectively aspirin is blocking platelets.

Study MapList of studies

Your Feedback

Return to header